IONIS PHARMACEUTICALS INC — Form 10-Q
Filed July 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 38/100
What the filing says
Ionis Pharmaceuticals and GSK amended their R&D and license agreement (Amendment #9, effective April 2, 2026) to restructure development and sales milestone payments specific to bepirovirsen in China, Hong Kong, and Macau. The amendment modifies Tables 3B, 4C, and 5C, establishing separate China Net Sales Milestones and royalty structures while adding obligations around NRDL process submissions and parallel trade monitoring. Most financial terms are redacted [***], limiting visibility into specific dollar amounts and thresholds, though previously-disclosed milestones include $1.5M (Phase 1 initiation, already paid), $15M each (Phase 3 initiation and first NDA filing, already paid), and $35M (approval in Major Country ex-China).
Why this rating
Material restructuring of existing long-term GSK partnership, but amendment is administrative refinement of China commercialization terms, not new deal. Redacted specifics limit impact assessment. Modest relative to $5.3B market cap.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.